Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 667-677

  Katz, Pamela M ^a   Leiter, Lawrence A ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ANACETRAPIB; ANTIOXIDANT; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTIPOL; CREATININE; DALCETRAPIB; EVACETRAPIB; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ATHEROMA; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FLUSHING; FOLLOW UP; GALLSTONE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; IC 50; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; DISEASE MANAGEMENT; HUMANS; RISK MANAGEMENT;

EID: 84869080523     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.03.017     Document Type: Review

References (109)

1. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
2. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
3. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
5. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-1357.
7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
8. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
9. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
10. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
11. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
12. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
13. Brown B.G. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. European Heart Journal Supplement 2005, 7:F34-F40.
14. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
15. Genest J.J., McNamara J.R., Salem D.N., et al. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991, 67:1185-1189.
16. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
17. Assmann G., Schulte H., von Eckardstein A., et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124:S11-S20.
18. Pekkanen J., Linn S., Heiss G., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990, 322:1700-1707.
19. Gordon T., Castelli W.P., Hjortland M.C., et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
20. Leiter LA, Fitchett DH, Gilbert RE, et al. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol;27:e1-33.
21. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
22. Cuchel M., Rader D.J. Genetics of increased HDL cholesterol levels: insights into the relationship between HDL metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:1710-1712.
23. Assmann G., Gotto A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004, 109:III8-III14.
24. Brewer H.B. The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 2011, 96:1246-1257.
25. Tabet F., Rye K.A. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 2009, 116:87-98.
26. Barter P.J., Nicholls S., Rye K.A., et al. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
27. O'Connell B.J., Genest J. High-density lipoproteins and endothelial function. Circulation 2001, 104:1978-1983.
28. Nofer J.R., Brodde M.F., Kehrel B.E. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 2010, 37:726-735.
29. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
30. Voight B.F., Peloso G.M., Orho-Melander M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580.
31. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998. Atheroscler Suppl 2004, 5:99-106.
32. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453-1460.
33. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297:499-508.
34. Briel M., Ferreira-Gonzalez I., You J.J., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
35. Ridker P.M., Genest J., Boekholdt S.M., et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010, 376:333-339.
36. Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
37. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
38. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
39. Brown B., Brockenbrough A., Zhao X.-Q., et al. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation 1998, 98:I-635.
40. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
41. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
42. Boden W.E., Probstfield J.L., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267. AIM-HIGH Investigators.
43. HPS2-THRIVE Accessed February 11, 2012. http://www.ctsu.ox.ac.uk/projects/hps2-thrive.
44. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
45. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
46. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27.
47. de Faire U., Ericsson C.G., Grip L., et al. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996, 17(suppl F):37-42.
48. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
49. Rajamani K., Colman P.G., Li L.P., et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009, 373:1780-1788.
50. Keech A.C., Mitchell P., Summanen P.A., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.
51. Chew E.Y., Ambrosius W.T., Davis M.D., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244.
52. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009, 54:810-819.
53. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
54. Ginsberg H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. ACCORD Study Group.
55. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
56. Barter P.J., Brewer H.B., Chapman M.J., et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160-167.
57. Sugano M., Makino N., Sawada S., et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998, 273:5033-5036.
58. Okamoto H., Yonemori F., Wakitani K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203-207.
59. Brown M.L., Inazu A., Hesler C.B., et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989, 342:448-451.
60. Koizumi J., Mabuchi H., Yoshimura A., et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985, 58:175-186.
61. Inazu A., Brown M.L., Hesler C.B., et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990, 323:1234-1238.
62. Hirano K., Yamashita S., Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 2000, 11:589-596.
63. Hirano K., Yamashita S., Nakajima N., et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997, 17:1053-1059.
64. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996, 97:2917-2923.
65. Moriyama Y., Okamura T., Inazu A., et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998, 27:659-667.
66. Thompson A., Di Angelantonio E., Sarwar N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008, 299:2777-2788.
67. Ridker P.M., Pare G., Parker A.N., et al. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009, 2:26-33.
68. Teslovich T.M., Musunuru K., Smith A.V., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
69. Vasan R.S., Pencina M.J., Robins S.J., et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009, 120:2414-2420.
70. Ritsch A., Scharnagl H., Eller P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2010, 121:366-374.
71. Regieli J.J., Jukema J.W., Grobbee D.E., et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 2008, 29:2792-2799.
72. Brousseau M.E., Schaefer E.J., Wolfe M.L., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
73. McKenney J.M., Davidson M.H., Shear C.L., et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006, 48:1782-1790.
74. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304-1316.
75. Bots M.L., Visseren F.L., Evans G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153-160.
76. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
77. Hu X., Dietz J.D., Xia C., et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009, 150:2211-2219.
78. Forrest M.J., Bloomfield D., Briscoe R.J., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008, 154:1465-1473.
79. Vergeer M., Bots M.L., van Leuven S.I., et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008, 118:2515-2522.
80. Connelly M.A., Parry T.J., Giardino E.C., et al. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J Cardiovasc Pharmacol 2010, 55:459-468.
81. Clerc R.G., Stauffer A., Weibel F., et al. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J Hypertens 2010, 28:1676-1686.
82. Nicholls S.J., Tuzcu E.M., Brennan D.M., et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008, 118:2506-2514.
83. Bloomfield D., Carlson G.L., Sapre A., et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157:352-360.e2.
84. Cannon C.P., Shah S., Dansky H.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363:2406-2415.
85. Stein E.A., Stroes E.S., Steiner G., et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009, 104:82-91.
86. Lüscher T.F., Taddei S., Kaski J.C., et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012, 33:857-868.
87. Nicholls S.J., Brewer H.B., Kastelein J.J., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306:2099-2109.
88. Schwartz G.G. New horizons for cholesterol ester transfer protein inhibitors. Curr Atheroscler Rep 2012, 14:41-48.
89. Ranalletta M., Bierilo K.K., Chen Y., et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010, 51:2739-2752.
90. Kastelein J.J., Duivenvoorden R., Deanfield J., et al. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation. Curr Med Res Opin 2011, 27:141-150.
91. Fayad Z.A., Mani V., Woodward M., et al. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J 2011, 162:214-221.e2.
92. Schwartz G.G., Olsson A.G., Ballantyne C.M., et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009, 158:896-901.e3.
93. A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease Accessed February 11, 2012. http://clinicaltrials.gov/ct2/show/NCT01059682.
94. Fayad Z.A., Mani V., Woodward M., et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011, 378:1547-1559.
95. Krishna R., Anderson M.S., Bergman A.J., et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007, 370:1907-1914.
96. REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification Accessed March 2, 2012. http://clinicaltrials.gov/ct2/show/NCT01252953.
97. Cao G., Beyer T.P., Zhang Y., et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011, 52:2169-2176.
98. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
99. Ansell B.J., Navab M., Hama S., et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108:2751-2756.
100. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
101. Sviridov D., Mukhamedova N., Remaley A.T., et al. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 2008, 15:52-62.
102. Duong M., Nicholls S.J. Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development. Expert Opin Drug Discov 2009, 4:753-761.
103. Niesor E.J., Magg C., Ogawa N., et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010, 51:3443-3454.
104. Niesor E.J. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol 2011, 22:288-295.
105. Yvan-Charvet L., Kling J., Pagler T., et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010, 30:1430-1438.
106. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
107. Waksman R., Torguson R., Kent K.M., et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010, 55:2727-2735.
108. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
109. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.